August 26, 2025
Hepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV). Commonly transmitted through blood-to-blood contact, it can cause serious long-term liver damage if left untreated. In this blog, we’ll explore everything you should know about hepatitis C from early signs and how it spreads, to advanced testing, modern antiviral drug treatments, lifestyle and diet tips, and emerging complications.
Hepatitis C refers to inflammation of the liver resulting from infection with HCV, a single-stranded RNA virus discovered in 1989. The virus primarily affects liver cells, causing damage through both direct viral effects and immune system responses.
“Know more about the basics of Hepatitis, you can also explore detailed information on Hepatitis A and Hepatitis B.”
Hepatitis C is a blood-borne disease:
Many individuals with acute HCV have no symptoms. When symptoms occur, they may include:
Hepatic manifestation:
Extrahepatic manifestations of hepatitis C are health conditions that occur outside the liver due to chronic HCV infection. These complications result from immune system activity triggered by the virus and may affect multiple organs. Common extrahepatic manifestations include:
These manifestations can occur even if liver disease is mild, and often improve or resolve after successful hepatitis C treatment.
Here’s what your doctor may request:
Test | Purpose |
Anti-HCV antibody (ELISA) | Shows past or current exposure to HCV |
HCV RNA (PCR) | Confirms active infection and monitors viral load |
Liver enzymes (ALT, AST) | Detects liver inflammation due to HCV |
Genotype test | Identifies HCV genotype to guide treatment |
Imaging (ultrasound/FibroScan) | Evaluates liver scarring (fibrosis) and cirrhosis |
Extrahepatic assessment | Checks for related conditions like kidney injury or rashes |
HCV is now curable in >95% of cases:
The introduction of Direct-Acting Antivirals (DAAs) has revolutionized hepatitis C treatment, turning a once-chronic, life-threatening condition into a highly curable disease for most patients. Unlike older interferon-based therapies, DAAs are taken orally, work quickly, and are associated with fewer side effects.
DAAs target specific steps in the hepatitis C virus (HCV) replication cycle. By blocking these steps, they stop the virus from multiplying, reduce liver inflammation, and ultimately lead to a sustained virologic response (SVR), which is considered a cure.
A recent 2025 clinical study confirmed that glecaprevir/pibrentasvir (Mavyret) achieved a 96% cure rate for acute hepatitis C within just 8 weeks of treatment.
Most patients tolerate DAAs very well. Reported side effects are generally mild and may include:
These are significantly fewer than with older treatments, making adherence easier and outcomes better.
Successful treatment leads to sustained virologic response (SVR) with no detectable HCV RNA months after therapy. This SVR reduces liver-related mortality by over 75%. Additionally, regular follow-up ensures liver recovery and helps address any complications.
Untreated chronic HCV can cause:
Cirrhosis is a condition where healthy liver tissue is gradually replaced by irreversible scar tissue (fibrosis), impairing the liver’s ability to function. This happens when chronic HCV inflammation continues unchecked over years or decades.
Cirrhosis symptoms may include:
Chronic hepatitis C significantly increases the risk of developing hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The risk is highest in patients with cirrhosis but can also occur in non-cirrhotic cases.
HCC often develops silently and may not cause symptoms until it is advanced. Regular surveillance with imaging (e.g., ultrasound every 6 months) and alpha-fetoprotein (AFP) blood testing is recommended for at-risk individuals
As liver function deteriorates, the body can no longer filter toxins effectively, particularly ammonia. These toxins accumulate and reach the brain, causing hepatic encephalopathy, a serious complication marked by:
This is often reversible with treatment, but recurrence is common in end-stage liver disease.
Liver failure (also known as end-stage liver disease or decompensated cirrhosis) occurs when the liver can no longer perform essential tasks such as:
Signs include severe jaundice, bleeding, ascites, infections, and encephalopathy. At this point, the only long-term solution may be a liver transplant.
like cryoglobulinemia, kidney disease, lichen planus, rash, and arthralgia.
In modern healthcare systems, all blood donations are rigorously screened for the hepatitis C virus (HCV). Still, individuals undergoing blood transfusions or organ transplants, especially in countries with limited resources, should be aware of the risks. At Reem Hospital, we adhere to strict HCV screening protocols to ensure safe transfusions.
Sharing needles, syringes, or any drug injection equipment is one of the most common ways hepatitis C spreads. To prevent transmission:
Tattooing and body piercing can carry a significant hepatitis C risk if equipment is not properly sterilized. To reduce this risk:
Healthcare workers are at risk of accidental needlestick injuries, which account for up to 3% transmission risk if exposed to HCV-positive blood. Hospitals minimize this with:
Patients also benefit from these standards, as they reduce the risk of cross-contamination during procedures like injections, surgery, or dental care.
Support your liver with:
Did You Know?
Hepatitis C is a serious but treatable liver disease. Early detection through hepatitis C blood tests and interventions with DAAs offers>95% cure rates. Lifestyle measures, safe practices, and follow-ups are critical. Reem Hospital provides comprehensive care—testing, treatment, monitoring, and patient support—to help you live hepatitis-free.